Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease

This is a unique report of two cases of patients with end-stage renal disease on hemodialysis, receiving ipilimumab for treatment of metastatic melanoma, as there is a paucity of safety and efficacy data in this patient subgroup.

Detalles Bibliográficos
Autores principales: Cavalcante, Ludimila, Amin, Asim, Lutzky, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304535/
https://www.ncbi.nlm.nih.gov/pubmed/25632239
http://dx.doi.org/10.2147/CMAR.S73389
_version_ 1782354123332517888
author Cavalcante, Ludimila
Amin, Asim
Lutzky, Jose
author_facet Cavalcante, Ludimila
Amin, Asim
Lutzky, Jose
author_sort Cavalcante, Ludimila
collection PubMed
description This is a unique report of two cases of patients with end-stage renal disease on hemodialysis, receiving ipilimumab for treatment of metastatic melanoma, as there is a paucity of safety and efficacy data in this patient subgroup.
format Online
Article
Text
id pubmed-4304535
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43045352015-01-28 Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease Cavalcante, Ludimila Amin, Asim Lutzky, Jose Cancer Manag Res Case Series This is a unique report of two cases of patients with end-stage renal disease on hemodialysis, receiving ipilimumab for treatment of metastatic melanoma, as there is a paucity of safety and efficacy data in this patient subgroup. Dove Medical Press 2015-01-19 /pmc/articles/PMC4304535/ /pubmed/25632239 http://dx.doi.org/10.2147/CMAR.S73389 Text en © 2015 Cavalcante et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Series
Cavalcante, Ludimila
Amin, Asim
Lutzky, Jose
Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
title Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
title_full Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
title_fullStr Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
title_full_unstemmed Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
title_short Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
title_sort ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304535/
https://www.ncbi.nlm.nih.gov/pubmed/25632239
http://dx.doi.org/10.2147/CMAR.S73389
work_keys_str_mv AT cavalcanteludimila ipilimumabwassafeandeffectiveintwopatientswithmetastaticmelanomaandendstagerenaldisease
AT aminasim ipilimumabwassafeandeffectiveintwopatientswithmetastaticmelanomaandendstagerenaldisease
AT lutzkyjose ipilimumabwassafeandeffectiveintwopatientswithmetastaticmelanomaandendstagerenaldisease

Ejemplares similares